International Journal of Urology · 2018 · 10 citations · 21 references
MedicineRadiologyUrologyDiagnostic ImagingDiagnostic RadiologyUltrasonographyCancer DetectionCancer DiagnosisProstate BiopsyProstate CancerProstate ImagingProstate-specific Antigen TestingBiopsy Of Prostate LesionsClinically Significant Prostate Cancer DetectionMagnetic Resonance Image FusionMagnetic Resonance Imaging - Targeted BiopsyMagnetic Resonance Imaging Fusion BiopsyTargeted Prostate BiopsyTransperineal UltrasonographyUltrasound Fusion Biopsy
OBJECTIVES: To evaluate the detection rates of clinically significant prostate cancer classified according to the prostate imaging reporting and data system scoring system using magnetic resonance imaging/ultrasound rigid fusion targeted biopsy. METHODS: A total of 339 patients underwent transperineal magnetic resonance imaging/ultrasound rigid fusion targeted biopsy in our institution between January 2015 and July 2017. Patients with prostate imaging reporting and data system category 1 or 2 and those with a pre-biopsy prostate-specific antigen value of >30 ng/mL were excluded from this study. Finally, 310 patients were recruited. RESULTS: The detection rates of clinically significant prostate cancer with prostate imaging reporting and data system category 3, 4, and 5 were 1.0% (1/98), 35.1% (47/134) and 73.1% (57/78), respectively. The factors affecting the detection of clinically significant prostate cancer with prostate imaging reporting and data system categories 4 and 5 were: (i) prostate imaging reporting and data system category 5; (ii) prostate volume <40 cc; (iii) no previous biopsy; (iv) lesion located in the peripheral zone; and (v) prostate-specific antigen density >0.35 ng/mL/mL. CONCLUSIONS: The detection rate of clinically significant prostate cancer on magnetic resonance imaging/ultrasound rigid fusion targeted biopsy is very low in patients with prostate imaging reporting and data system category 3; therefore, patients with this classification should not undergo targeted biopsy. Prostate-specific antigen density, prostate volume, locations of suspected cancer and history of biopsy should be considered to predict the detection rate of clinically significant prostate cancer with prostate imaging reporting and data system categories 4 and 5.
21
ESUR prostate MR guidelines 2012
Jelle O. Barentsz, Jonathan Richenberg, R. Clements et al. · European Radiology · 2012 · 2.4K citations · Full text
Morgan Pokorny, Maarten de Rooij, Earl Duncan et al. · European Urology · 2014 · 503 citations
Mohummad Minhaj Siddiqui, Soroush Rais‐Bahrami, Lambros Stamatakis et al. · European Urology · 2013 · 502 citations · Full text
PROSPECTIVE EVALUATION OF PROSTATE CANCER DETECTED ON BIOPSIES 1, 2, 3 AND 4: WHEN SHOULD WE STOP?
Bob Djavan, V. Ravery, A. Zlotta et al. · The Journal of Urology · 2001 · 448 citations